Assertio Therapeutics Inc

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Assertio Therapeutics Inc reports stellar Q4 performance and growth outlook

Assertio Therapeutics Inc (ASRT) delivered a robust Q4 performance with significant revenue and profit growth, despite facing challenges like supply issues.
The company's strategic focus on marketing, product development, and business expansion highlights a commitment to long-term success and shareholder value.
With a positive outlook for 2023 and a strong foundation in place, ASRT is poised for continued growth and value creation in the pharmaceutical market.

Assertio Therapeutics Inc (ASRT) reports robust Q1 results and raises 2023 guidance

Assertio Therapeutics Inc (ASRT) demonstrated solid financial performance in Q1 2023, with strong sales growth and improved profitability.
The company's strategic execution and upcoming acquisitions signal a positive outlook for future growth and expansion.
While facing integration challenges and market competition, Assertio's focus on product sales and operational efficiency bodes well for sustained success.

Assertio Therapeutics reports strong Q2 growth amidst generic competition

Assertio's Q2 performance showcased growth driven by key products and the acquisition of Spectrum Pharmaceuticals, positioning the company for future success.
While facing challenges from generic competition and operational expenses, Assertio remains focused on defending market share and creating shareholder value.
Management's confidence in overcoming short-term obstacles underscores a proactive approach to navigating market dynamics and driving growth.

Assertio Therapeutics Inc reports resilient Q3 performance amidst challenges

Assertio Therapeutics Inc navigated challenges in Q3 2023 with resilience, reporting positive financial metrics and improved liquidity.
New management changes and a focus on market access signal the company's commitment to driving growth and optimizing operations.
Despite lower sales for certain products, Assertio's strategic initiatives and financial performance position it well for future opportunities.
Analyst inquiries during the call highlighted areas for improvement and growth, indicating a proactive approach to addressing market dynamics.

Assertio Therapeutics reports robust Q4 results and outlines growth plans

Assertio Therapeutics Inc (ASRT) demonstrated strong financial performance in Q4 2023, driven by robust sales and positive EBITDA.
The company's strategic focus on Rolvedon's growth, profitability optimization, and future acquisitions positions it well for continued success.
While facing challenges from generic competition and operational issues, Assertio is poised to capitalize on growth opportunities and drive value creation.

Assertio Therapeutics Inc meets Q1 targets, eyes growth opportunities

Assertio Therapeutics Inc's Q1 2024 showcased strong sales performance, cost management, and cash generation. Despite challenges in generic competition and CEO transition, the company remains focused on growth opportunities.

Assertio Therapeutics reports solid Q2 results and projects growth

Assertio Therapeutics Inc (ASRT) demonstrated financial stability, growth potential, and resilience in the face of market challenges during Q2 2024.
The company's strategic focus on key products like Rolvedon and effective cost management strategies position it well for future success and profitability.
Maintaining guidance for 2024 and leveraging opportunities for growth underscore Assertio's commitment to delivering value to shareholders and stakeholders.

Assertio Therapeutics reports stable Q3 performance amid ROLVEDON transition

Assertio Therapeutics demonstrated stable financial performance and operational efficiency in Q3 2024, positioning the company for growth amidst challenges.
The company's focus on ROLVEDON and governance enhancements signal a strategic shift towards innovation and stakeholder value creation.
While facing challenges such as declining product sales and financial constraints, Assertio remains resilient and poised to capitalize on opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Letter Expresses Several Significant Concerns and Recommends That Further Investigation is Warranted Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors  or Force Resignations of Significant Portion of Board Pursuant to Bylaws NEW YORK , May 17, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), today released a letter from Rumbi B. Petrozzello, a Certified Public Accountant and Certified Fraud Examiner who previously served as President of the New York State Society of CPAs.

BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS

LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Alliance Global Partners Virtual Healthcare Company Showcase to be held virtually on May 21, 2024. Mr. Patel will present an overview of Assertio's business at 3:40 p.m. Eastern Time.

Assertio to Participate in AGP Healthcare Conference on May 21

Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to Bylaws Board and Management Inappropriately Answered or Refused to Answer Questions Over Very Material Matters Believes Insiders May Have Not Personally Purchased Shares in Over Three Years Due to Material Non-Public Information Last Remaining Investor-Minded Advocate on Board Has Chosen to Step Down Over Inappropriate Boardroom Activity, Leaving a Largely Out-of-Touch Board Analysts Have Dropped Coverage of Assertio Due to What Appears to be Lost Faith in Leadership's Due Diligence Abilities, Reinforcing BHG's Concerns Intends to Imminently Release Third-Party Expert Opinions Concerning Assertio Board and Management's Apparent Disclosure Failures and Deficiencies, for Further Delivery to Regulators Believes Board Should Promptly Explore Strategic Alternatives, Including a Possible Sale, Given Significant Opportunity to Achieve Post-Acquisition Operating Profit Enhancement through Reduced SG&A Expenses NEW YORK , May 13, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) urges Assertio stockholders to vote "against" all of the Company's director nominees at the Company's upcoming 2024 annual meeting of stockholders on May 23, 2024 (the "Annual Meeting"). BHG strongly believes that significant change to the Assertio board of directors (the "Board") is necessary in order to bring about new oversight and reinstate stockholder-like judgment in the Boardroom.

BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS

LAKE FOREST, Ill., May 10, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference to be held May 13, 2024 in New York City.

Assertio to Present at the Citizens JMP Life Sciences Conference in New York City

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO Paul Schwichtenberg - Chief Commercial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets Operator Good afternoon, and welcome to Assertio Holdings First Quarter 2024 Financial Results Call. [Operator Instructions] I would now like to turn the call over to Matt Kreps, Investor Relations for the company.

Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript

First Quarter Net Product Sales of $31.9 Million

Assertio Reports First Quarter 2024 Financial Results

LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024

LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.

Assertio to Present at LD Micro Invitational Conference in New York City

Assertio Holdings Inc. (NASDAQ:ASRT ) Q4 2023 Earnings Conference Call March 11, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO Paul Schwichtenberg - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Operator Thank you for standing by, and welcome to the Assertio Holdings Fourth Quarter and Full Year 2023 Results Call. I would now like to welcome Matt Kreps, Investor Relations for the company to begin the call.

Assertio Holdings Inc. (ASRT) Q4 2023 Earnings Call Transcript

Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million

Assertio Reports Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69322&wire=1 or contact Joseph E. Levi, Esq.

Assertio Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT

NEW YORK , March 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Assertio Holdings, Inc.. Shareholders who purchased shares of ASRT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69255&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 5, 2024 in Assertio Holdings Lawsuit - ASRT

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69257&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69171&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc.(ASRT) Shareholders

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69137&wire=1 or contact Joseph E. Levi, Esq.

Assertio Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 5, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) securities between March 9, 2023 and November 8, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On August 3, 2023, the U.S. Food and Drug Administration.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69111&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Assertio Holdings, Inc.(ASRT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69107&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Assertio Holdings Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT

PHILADELPHIA , March 4, 2024 /PRNewswire/ -- Nationally recognized law firm,  Berger Montague PC , informs investors that a lawsuit was filed against Assertio Holdings, Inc. ("Assertio") (NASDAQ: ASRT) on behalf of purchasers of Assertio's securities between March 9, 2023 and November 8, 2023, inclusive (the "Class Period"). Investors that suffered losses from Assertio Holdings, Inc. (NASDAQ: ASRT) investments can follow the link below for more information regarding the lawsuit: CLICK HERE  to learn more about the lawsuit.

CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Assertio Holdings, Inc. (NASDAQ: ASRT) Investors to Inquire About a Securities Fraud Class Action by March 5, 2024

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69016&wire=1 or contact Joseph E. Levi, Esq.

Assertio Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ASRT

NEW YORK, NY / ACCESSWIRE / March 3, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=68957&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Assertio Holdings, Inc.(ASRT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / March 3, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=68919&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT). The class action, filed in the United States District Court for the Northern District of Illinois, and docketed under 23-cv- 00169, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Assertio securities between March 9, 2023 and November 8, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - ASRT

NEW YORK, NY / ACCESSWIRE / March 3, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=68907&wire=1 or contact Joseph E. Levi, Esq.

News for Assertio Therapeutics Inc Stock (ASRT)